Metamizol Ratiopharm (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels decrease pain signal sensitization and lower the hypothalamic set‑point for body temperature, providing analgesic and antipyretic effects.

The appropriate dose of Metamizol Ratiopharm is determined by the prescribing clinician based on the patient’s condition, age, weight, and response. Dosage regimens may vary, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Metamizol Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole belongs to the pyrazolone class, whereas most common over‑the‑counter analgesics are NSAIDs. Both reduce pain and fever, but metamizole has a distinct mechanism and a lower risk of gastrointestinal irritation. However, it carries a rare risk of agranulocytosis, which is not typical for standard NSAIDs.

Metamizol Ratiopharm tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metamizol Ratiopharm is administered orally. The tablets are swallowed whole with water and should be taken exactly as prescribed by a qualified healthcare professional, typically with or without food depending on the prescriber’s guidance.

The most serious adverse reactions to metamizole include agranulocytosis, a potentially fatal reduction in white blood cells, and severe allergic responses such as anaphylactic shock or Stevens‑Johnson syndrome. Prompt medical attention is required if signs of infection, rash, or breathing difficulties occur.

Metamizol Ratiopharm should be avoided in patients with known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis, and individuals receiving concurrent myelotoxic chemotherapy unless closely monitored. Caution is also advised for patients with severe renal or hepatic impairment.